An investment from Aflac Ventures and Artiman Ventures is financing the agreement, according to a March 23 press release. CellMax has also received series C financing for the test.
CellMax’s multimodal liquid biopsy test, FirstSight, is a noninvasive screening method for detection of colorectal cancer and precancerous polyps.
Sebela is a pharmaceutical company and a key player in the gastroenterology market. CellMax Life is a diagnostics company focused on cancer screening.
More articles on ASCs:
Michigan orhopedic group reports breach that exposed 28,658 patients’ information
7 developments in outpatient spine surgery in 2021
4 key questions on the future of spine surgery at ASCs
